SAFETY OF CYTOTOXIC CHEMOTHERAPY FOLLOWING RADIUM-223 CHLORIDE (RA-223) THERAPY IN THE PHASE 3 ALSYMPCA STUDY IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC) WITH BONE METASTASES

被引：0
|
作者：
Sartor, O. [1 ,2 ]
Coleman, R. E. [3 ]
Nilsson, S. [4 ]
Vogelzang, N. [5 ]
Cross, A. [6 ]
O'Bryan-Tear, G. [7 ]
Staudacher, K. [7 ]
Garcia-Vargas, J. E. [8 ]
Zou, J. [9 ]
Parker, C. [10 ]
机构：
[1] Tulane Canc Ctr, Sect Hematol & Med Oncol, Dept Med, New Orleans, LA USA
[2] Tulane Canc Ctr, Dept Urol, New Orleans, LA USA
[3] Weston Pk Hosp, Acad Unit Clin Oncol, Sheffield, S Yorkshire, England
[4] Karolinska Univ Hosp, Radiumhemmet, Stockholm, Sweden
[5] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
[6] PharmaNet, Biostat, Hemel, Hempstead, England
[7] Algeta ASA, Oslo, Norway
[8] Bayer HealthCare Pharmaceut, Oncol Global Clin Programs, Montville, NJ USA
[9] Bayer HealthCare Pharmaceut, Global Med Affairs, Montville, NJ USA
[10] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：308 / 309
页数：2
相关论文
共 50 条
  • [41] Radium-223 chloride: Radiation safety, tolerability, and survival gain in patients with castration-resistant prostate cancer (CRPC) and bone metastases
    Lewington, Valerie
    Lamey, Roy
    Staudacher, Karin
    Vogelzang, Nicholas
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [42] Radium-223 Chloride Safety and Use of External Beam Radiation Therapy (EBRT) in the Phase HI Randomized Trial (ALSYMPCA) in Patients With Castration-resistant Prostate Cancer (CRPC) and Bone Metastases
    Sandler, H. M.
    Nilsson, S.
    Parker, C.
    Garcia-Vargas, J.
    Staudacher, K.
    Hoskin, P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S3 - S4
  • [43] Time to first skeletal-related event (SRE) with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases: ALSYMPCA trial stratification factors analysis
    Coleman, R.
    Fossa, S.
    Chodacki, A.
    Wedel, S.
    Bruland, O.
    Staudacher, K.
    Garcia-Vargas, J.
    Sartor, O.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S688 - S688
  • [44] Effects of radium-223 dichloride (Ra-223) on total alkaline phosphatase (ALP) and prostate-specific antigen (PSA) in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA trial
    Strauss, A.
    Heinrich, D.
    Parker, C.
    Shan, M.
    Wilhelm, S.
    Garcia-Vargas, J.
    O'Bryan-Tear, C. G.
    Sartor, O.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 177 - 178
  • [45] Radium-223 chloride (Ra-223) impact on skeletal-related events (SREs) and ECOG performance status (PS) in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Interim results of a phase III trial (ALSYMPCA)
    Sartor, A. Oliver
    Heinrich, Daniel
    O'Sullivan, Joe M.
    Fossa, Sophie D.
    Chodacki, Ales
    Wiechno, Pawel J.
    Logue, John P.
    Seke, Mihalj
    Widmark, Anders
    Johannessen, Dag Clement
    Nilsson, Sten
    Hoskin, Peter
    Bottomley, David
    Coleman, Robert Edward
    Vogelzang, Nicholas J.
    O'Bryan-Tear, C. Gillies
    Garcia-Vargas, Jose E.
    Shan, Minghua
    Parker, Chris
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [46] Updated analysis of radium-223 dichloride (Ra-223) impact on skeletal-related events (SRE) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase III randomized trial (ALSYMPCA)
    Vogelzang, Nicholas J.
    Parker, Chris
    Nilsson, Sten
    Coleman, Robert Edward
    O'Bryan-Tear, C. Gillies
    Shan, Minghua
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [47] Imaging response during therapy (tx) with radium-223 (Ra-223) for castrate resistant prostate cancer (CRPC) with bone metastases (BM)
    Keizman, Daniel
    Peer, Avivit
    Neumann, Avivit
    Rosenbaum, Eli
    Neiman, Victoria
    Gottfried, Maya
    Kuchuk, Iryna
    Sarid, David
    Gez, Eliahu
    Mermershtain, Wilmosh
    Rouvinov, Keren
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [48] 1.5-YEAR POSTTREATMENT FOLLOW-UP OF RADIUM-223 DICHLORIDE (RA-223) SAFETY IN PATIENTS (PTS) WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC) AND SYMPTOMATIC BONE METASTASES FROM ALSYMPCA: CHARACTERIZATION OF HEMATOLOGIC SAFETY PROFILES
    Parker, C.
    Vogelzang, N.
    Sartor, O.
    Bottomley, D.
    Coleman, R. E.
    Skjorestad, I.
    Aksnes, A.
    Wahba, M.
    Nilsson, S.
    ANNALS OF ONCOLOGY, 2014, 25
  • [49] Radium-223 chloride impact on skeletal-related events in patients with castration-resistant prostate cancer (CRPC) with bone metastases: A phase III randomized trial (ALSYMPCA)
    Sartor, A. Oliver
    Heinrich, Daniel
    Helle, Svein Inge
    O'Sullivan, Joe M.
    Fossa, Sophie D.
    Chodacki, Ales
    Demkow, Tomasz
    Logue, John P.
    Seke, Mihalj
    Widmark, Anders
    Johannessen, Dag Clement
    Nilsson, Sten
    Hoskin, Peter
    Solberg, Arne
    James, Nicholas David
    Syndikus, Isabel
    Vogelzang, Nicholas J.
    O'Bryan-Tear, C. Gillies
    Shan, Minghua
    Parker, Chris
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [50] Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA).
    Parker, Chris
    Nilsson, Sten
    Heinrich, Daniel
    O'Sullivan, Joe M.
    Fossa, Sophie D.
    Chodacki, Ales
    Wiechno, Pawel J.
    Logue, John P.
    Seke, Mihalj
    Widmark, Anders
    Johannessen, Dag Clement
    Hoskin, Peter
    Bottomley, David
    Coleman, Robert Edward
    Vogelzang, Nicholas J.
    O'Bryan-Tear, C. Gillies
    Garcia-Vargas, Jose E.
    Shan, Minghua
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345